Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LDFRT with Gemcitabine and Cisplatin in Intrahepatic Cholangiocarcinoma
NCT02254681Phase 2Terminated
- Sponsor
- Allina Health
- Start
- Sep 2014
- Primary completion
- Sep 2016
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in intrahepatic cholangiocarcinoma (ICC), sponsored by Allina Health. Primary endpoints: Number of Participants With Radiographic Disease Response at 16 weeks and Number of Participants With Adverse Events at 16 weeks. Started Sep 2014; status: terminated.
02
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT02254681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02254681.